March 22 (Reuters) - Protagonist Therapeutics Inc :
* PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
* PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
* PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)